Goldman Sachs initiated coverage of AstraZeneca with a Buy rating and $97 price target. The analyst believes the company offers an attractive combination of a strong underlying business with room for margin expansion, coupled with an unrivaled pipeline optionality driven by a “best-in-class” pipeline and track record of execution. The firm is “intrigued” by AstraZeneca’s opportunity set in obesity and cardiometabolic diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca says Dato-DXd showed meaningful OS improvement in trial
- AstraZeneca price target raised to 14,500 GBp from 14,000 GBp at Morgan Stanley
- Jefferies healthcare analyst holds an analyst/industry conference call
- AstraZeneca to present ‘more than’ 100 abstracts regarding SCLC and MBV at ASCO
- AstraZeneca (NASDAQ:AZN) Aims for $80B Annual Revenue by 2030